trial · primary record
GTX-102
Angelman Syndrome
| Phase | Phase 3 |
|---|---|
| Status | TERMINATED |
| Sponsor | Unknown |
| Enrolment | 66 |
| Primary completion | 2026-10-30 |
| Primary endpoint | Incidence of Treatment Emergent Adverse Events (TEAEs) |
| Registry ID | NCT06415344 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:30.254Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06415344
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Gtx-102 · compound